Citius Oncology, Inc. Increase (Decrease) in Accounts Receivable
Citius Oncology, Inc. (CTOR) reported Increase (Decrease) in Accounts Receivable of $686.24 thousand for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-14
- Citius Oncology, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$392.82K.
- Citius Oncology, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$2.97M.
- Citius Oncology, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $4.05M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month |
|---|---|---|---|
| 2026-06-30 | -$392.82K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-14 | -$3.36M derived: sum of 2 quarters · filed 2026-08-14 | $686.24K 10-Q · filed 2026-08-14 |
| 2026-03-31 | -$2.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | $1.08M 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $4.05M 10-Q · filed 2026-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |